Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study will compare the effects of AXA1125, an orally active mixture of amino acids,
compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis
in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability
of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice
daily, and a liver biopsy will be done at the beginning and end of the 48-week study.